The efficacy of topical

Hemorrhoid disease Randomized controlled trial Sodium pentaborate pentahydrate

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 15 12 2023
revised: 23 02 2024
accepted: 26 02 2024
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 11 3 2024
Statut: epublish

Résumé

The topical application of boron has been significantly associated with intensifying wound healing. Using 3% boric acid in deep wounds significantly contributes to wound healing and reduces the duration of hospitalization in the intensive care. The objective of this study was to assess the therapeutic impact of a topical gel containing In this randomized double-blind placebo-controlled trial, we applied a topical gel consisting of Before the intervention, symptom severity (p > 0.05) and anoscopy findings (p = 0.815) were similar between the two groups. Subsequent to the intervention, a majority of patients in the intervention group experienced a reduction in anal itching compared to the placebo group [adjusted mean difference (aMD) 95% CI: -1.98 (-2.2 to -1.8), p = 0.007]. Moreover, resting pain [aMD (95% CI): -1.37 (-1.6 to -1.1), p = 0.015], pain during defecation [aMD (95% CI): -2.19 (-2.4 to -2.0), p = 0.005], feeling a lump in the anus (aMD (95% CI): -0.71 (-1.2 to -0.2), p = 0.011), bleeding during defecation (41.7% vs. 66.9%, p = 0.027), and hemorrhoid degree (p < 0.001) in the intervention group was less than the placebo group. Our findings indicate the effectiveness of the study gel on hemorrhoid symptoms and anoscopy findings in patients.

Sections du résumé

Background UNASSIGNED
The topical application of boron has been significantly associated with intensifying wound healing. Using 3% boric acid in deep wounds significantly contributes to wound healing and reduces the duration of hospitalization in the intensive care. The objective of this study was to assess the therapeutic impact of a topical gel containing
Methods UNASSIGNED
In this randomized double-blind placebo-controlled trial, we applied a topical gel consisting of
Results UNASSIGNED
Before the intervention, symptom severity (p > 0.05) and anoscopy findings (p = 0.815) were similar between the two groups. Subsequent to the intervention, a majority of patients in the intervention group experienced a reduction in anal itching compared to the placebo group [adjusted mean difference (aMD) 95% CI: -1.98 (-2.2 to -1.8), p = 0.007]. Moreover, resting pain [aMD (95% CI): -1.37 (-1.6 to -1.1), p = 0.015], pain during defecation [aMD (95% CI): -2.19 (-2.4 to -2.0), p = 0.005], feeling a lump in the anus (aMD (95% CI): -0.71 (-1.2 to -0.2), p = 0.011), bleeding during defecation (41.7% vs. 66.9%, p = 0.027), and hemorrhoid degree (p < 0.001) in the intervention group was less than the placebo group.
Conclusion UNASSIGNED
Our findings indicate the effectiveness of the study gel on hemorrhoid symptoms and anoscopy findings in patients.

Identifiants

pubmed: 38463771
doi: 10.1016/j.heliyon.2024.e27215
pii: S2405-8440(24)03246-8
pmc: PMC10923721
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e27215

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Fikrettin Şahin (F)

Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.

Azizeh Farshbaf-Khalili (A)

Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Science, Tabriz, Iran.

Samin Alihosseini (S)

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Parvin Sarbakhsh (P)

Department of Statistics and Epidemiology School of Public Health, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Sadegh Pirouzpanah (MS)

Faculty of Medicine, Research & Development Office, Satin Tan Kimia co, Pharmaceutical Incubator, Tabriz University of Medical Sciences, Tabriz, Iran.

Erhan Ayşan (E)

Faculty of Medicine, Department of General Surgery, Yeditepe University, Istanbul, Turkey.

Ayşegül Doğan (A)

Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.

Afshin Gharekhani (A)

Drug Applied Research Center, Sina Hospital, Department of Clinical Pharmacy (Pharmacotherapy), Tabriz University of Medical Sciences, Tabriz, Iran.

Manouchehr Khoshbaten (M)

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad-Bagher Pirouzpanah (MB)

Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

Classifications MeSH